{"nctId":"NCT03176693","briefTitle":"Preoperative Alpha Blockade for Pheochromocytoma","startDateStruct":{"date":"2017-05-05","type":"ACTUAL"},"conditions":["Pheochromocytoma","Paraganglioma"],"count":39,"armGroups":[{"label":"Phenoxybenzamine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Phenoxybenzamine"]},{"label":"Doxazosin","type":"EXPERIMENTAL","interventionNames":["Drug: Doxazosin"]}],"interventions":[{"name":"Phenoxybenzamine","otherNames":["Dibenzyline"]},{"name":"Doxazosin","otherNames":["Cardura"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults with pheochromocytoma / paraganglioma undergoing surgical resection\n\nExclusion Criteria:\n\n* Children \\< 18 years","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemodynamic Instability","description":"Proportion of operative time outside target thresholds: SBP \\>180 or \\<80; DBP \\> 90; MAP\\>150 or \\<50; HR\\>90.\n\nArterial line blood pressure measurements were extracted from the electronic medical record every 60 seconds.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Mortality","description":"Death within 30 days of surgery","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Daily Cost of Drug","description":null,"paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"442.20","spread":null},{"groupId":"OG001","value":"5.06","spread":null}]}]}]},{"type":"SECONDARY","title":"Quality of Life- Physical Functioning, Role Limitations Due to Physical Problems, Bodily Pain, General Health Perceptions, Vitality, Social Functioning, Role-limitations Due to Emotional Problems, and Mental Health","description":"Patients will take the SF-36 as well as a symptom survey describing the frequency and impact on their quality of life at several time points including prior to starting alpha blockade, immediately prior to surgery after being sufficiently blocked, and postoperatively at 30 days, 3 months, 6 months, and 1 year","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Morbidity as Assessed by Occurrence of Adverse Events","description":"Morbidity will be graded by Clavien Classification of adverse events","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Admitted to Post-operative Intensive Care Unit (ICU)","description":null,"paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":19},"commonTop":[]}}}